Creating systemic oral transmucosal drug delivery strategies: Case study of APL-130277
This article addresses the strategic application of systemic oral transmucosal* (i.e., sublingual and buccal) drug delivery. Circumvention of first-pass hepatic metabolism in the gut, rapid onset of action, easy access via the oral cavity, easy administration for patients with dysphagia and a high level of patient acceptance are the principal advantages of the oral transmucosal route. Key clinical and commercial strategies driving the development of oral transmucosal formulations are addressed. A case study of Cynapsus Therapeutics’ APL-130277, a sublingual apomorphine formulation in clinical development for Parkinson’s disease exemplifies the scientific, clinical and commercial considerations for systemic oral transmucosal drug delivery.
*Note: In this article, oral transmucosal delivery refers to systemic drug delivery through the sublingual or buccal mucosa. Local delivery to the oral mucosa is not included.
Full details at the Journal of Commercial Biotechnology
Comments are closed.